GlobeNewswire·Nov 9, 2026, 6:35 AM ET

Abeona Therapeutics® Reports Third Quarter 2026 Financial Results and ZEVASKYN® Commercial Progress

Abeona Therapeutics reported Q3 2026 net ZEVASKYN revenue of $13.5 million, representing an 18% sequential increase over Q2.
15 total ZEVASKYN treatments have been completed since launch, with six performed during the third quarter.
The Qualified Treatment Center (QTC) network expanded to eight sites, with four centers now having completed patient treatments.
ZEVASKYN New Technology Add-On Payment (NTAP) status became effective on October 1, 2026.
Cash, cash equivalents, & short-term investments totaled $134.9 million as of September 30, 2026.
The company announced the acquisition of Phase 3-ready APT-1011 (now ABO-801) for eosinophilic esophagitis in exchange for $20 million in common stock & potential milestone payments.
A separate $30 million Private Investment in Public Equity (PIPE) financing was announced for general corporate purposes.
Net loss for the quarter was $4.8 million, or $0.08 per share, compared to a $20.2 million loss in the second quarter.
Abeona may receive future royalties & milestone payments from Ultragenyx following FDA approval of FAYUVI, which was previously advanced by Abeona.
The company scheduled a conference call for November 9, 2026, to discuss Q3 results, commercial progress, & the new asset acquisition.